RT Journal Article
SR Electronic
T1 Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.27.20163188
DO 10.1101/2020.07.27.20163188
A1 Cheng, Alexandre Pellan
A1 Cheng, Matthew Pellan
A1 Gu, Wei
A1 Lenz, Joan Sesing
A1 Hsu, Elaine
A1 Schurr, Erwin
A1 Bourque, Guillaume
A1 Bourgey, Mathieu
A1 Ritz, Jerome
A1 Marty, Francisco
A1 Chiu, Charles Y.
A1 Vinh, Donald Cuong
A1 De Vlaminck, Iwijn
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.27.20163188.abstract
AB COVID-19 primarily affects the lungs, but evidence of systemic disease with multi-organ involvement is emerging. Here, we developed a blood test to broadly quantify cell, tissue, and organ specific injury due to COVID-19, using genome-wide methylation profiling of circulating cell-free DNA in plasma. We assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls. We found evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. The concentration of cfDNA correlated with the WHO ordinal scale for disease progression and was significantly increased in patients requiring intubation. This study points to the utility of cell-free DNA as an analyte to monitor and study COVID-19.Competing Interest StatementA.P.C., M.P.C., W.G., C.Y.C., D.C.V. and I.D.V. are inventors on a patent application submitted by Cornell University Center for Technology Licensing.Funding StatementThis work was supported by NIH Grant 1DP2AI138242 (to I.D.V.), R01AI146165 (to I.D.V. and M.P.C), 1R01AI151059 (to I.D.V.), K08-CA230156 (to W.G), R33-AI129455 to C.Y.C, a Synergy award from the Rainin Foundation (to I.D.V.), a SARS-CoV-2 seed grant at Cornell (to I.D.V.), a National Sciences and Engineering Research Council of Canada fellowship PGS-D3 (to A.P.C.), and Burroughs-Wellcome CAMS Award (to W.G.). D.C.V. is supported by a Fonds de la recherche en sante du Quebec Clinical Research Scholar Junior 2 award. C.Y.C. is supported by the California Initiative to Advance Precision Medicine, and the Charles and Helen Schwab Foundation (C.Y.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCSF Institutional Review Board (protocol number 10-00476, 18-25287), McGill University Health Center Research Ethics Board protocol 10-256, Cornell Institutional Review Board (protocol number 1910009101)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data will be hosted on the Sequence Read Archive. The code used to generate figures and analyze primary data is available at www.github.com/alexpcheng/cfDNAme.